Methods Chemo-nave stage IIIB/IV or postoperative recurrent SCC pts were randomly assigned to receive either cisplatin (80 mg/m2) on day 1 plus gemcitabine (1000 mg/m2) on days 1, 8 every 3 weeks or CBDCA (AUC 6 mg/ml/min) on day 1 plus nab-PTX (75 mg/m2) on days 1, 8, ...
Patients received 100mg/m2nabPTX weekly and CBDCA at area under the concentration-time curve (AUC) 6 once every 3 weeks for 4-6 cycles. The primary endpoint was overall response rate (ORR); secondary endpoints included toxicity, progression-free survival (PFS) and overall survival (OS). ...
P1.01-33 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR study)doi:10.1016/j.jtho.2018.08.589Harada, T.Udagawa, H.Sugiyama, E.Atagi, S.Koyama, R.Watanabe, S.
P3.01-42 Phase II Trial Allowed Surgery After Induction Chemotherapy of CBDCA+PTX, Bevacizumab in Patients with Stages IIIA-IV Nonsquamous NSCLC - ScienceDirectdoi:10.1016/j.jtho.2018.08.1602K. ImaiT. NakagawaI. MatsuzakiK. OrinoH. Saito...
P1.01-08 Randomized Phase II Trial of CBDCA+nab-PTX vs CDDP+GEM in Patients with Chemo-Nave Squamous Cell Lung Cancer: NJLCG1302doi:10.1016/j.jtho.2019.08.723T. HaradaY. KawashimaY. FujitaT. NakagawaK. WatanabeN. MorikawaK. Takamura...